- 主题
- 46
- 您的身份
- 病友
- 病理报告
- 皮下脂膜炎样t细胞淋巴瘤
- 目前状态
- 治疗中
参加活动:0 次 组织活动:0 次
您的身份病友
病理报告皮下脂膜炎样t细胞淋巴瘤
目前状态治疗中
最后登录2024-11-19
|
发表于 2022-9-19 11:18:15
来自手机
|
显示全部楼层
来自: 中国
橙色雨丝 发表于 2022-09-19 11:07
国内对皮下脂膜炎样T细胞淋巴瘤的治疗,与国外文献上报道的很不一样,国内血液科与皮肤科对这种疾病的治疗,也有较大的区别,我不知道哪一种策略更为合适,只能在最近的一份文献里摘一段话给你看,这段话大致总结了目前的一些做法:
No standardized treatment protocol currently exists for SPTCL. Historically, polychemotherapy was used for treatment. However, following the 2008 World Health Organization–European Organization for Research and Treatment of Cancer update excluding the more aggressive γ/δ phenotype,3 systemic corticosteroids were shown to be an effective first-line therapy for SPTCL without HLH.7 Further evidence has demonstrated higher rates of complete remission and lower rates of progression with immunosuppressant therapies in SPTCL.8
Success has also been reported with bexarotene9 and romidepsin monotherapy.10 In the case presented, cyclosporine and prednisone therapy resulted in significant improvement with resolution of induration and erythema, systemic symptoms, and subcutaneous nodules. This case adds to accumulating data favoring the use of immunosuppressive agents as first-line treatment for SPTCL rather than chemotherapy. (https://doi.org/10.1016/j.jdcr.2022.08.006)
目前尚无针对SPTCL的标准化治疗方案。历史上,采用多药化疗进行治疗。然而,在2008年世界卫生组织-欧洲癌症研究和治疗组织更新排除更具侵袭性的γ/δ表型后,系统性糖皮质激素被证明是无并发HLH(嗜血细胞综合征)的SPTCL的有效一线治疗。进一步的证据表明,SPTCL采用免疫抑制疗法的完全缓解率较高,进展率较低。贝沙罗汀和罗米地辛单药治疗也取得了成功。在本病例中,环孢素A和泼尼松治疗可显著改善硬化和红斑、全身症状和皮下结节。该病例增加了支持使用免疫抑制剂作为SPTCL一线治疗而非化疗的数据积累。
谢谢雨丝大神,意思是需要终身用激素,对么?用激素人不就毁了么? |
|